{"id":1901084,"date":"2026-04-22T21:00:00","date_gmt":"2026-04-22T18:00:00","guid":{"rendered":"https:\/\/analyse.optim.biz\/?p=1901084"},"modified":"2026-04-22T21:00:00","modified_gmt":"2026-04-22T18:00:00","slug":"cancer-pediatric-unda-verde-conditionata-in-europa-pentru-un-tratament-al-companiei-ipsen","status":"publish","type":"post","link":"https:\/\/analyse.optim.biz\/?p=1901084","title":{"rendered":"Cancer pediatric\/ Und\u0103 verde condi\u021bionat\u0103 \u00een Europa pentru un tratament al companiei Ipsen"},"content":{"rendered":"<p>[analyse_image type=&#8221;featured&#8221; src=&#8221;https:\/\/www.monitoruldevrancea.ro\/wp-content\/uploads\/2026\/04\/Cancer-pediatric.jpg&#8221;]<\/p>\n<div class=\"td_block_wrap tdb_single_content tdi_123 td-pb-border-top td_block_template_1 td-post-content tagdiv-type\" data-td-block-uid=\"tdi_123\">\n<div class=\"tdb-block-inner td-fix-index\">\n<p>Grupul farmaceutic francez Ipsen a anun\u021bat miercuri c\u0103 a ob\u021binut o \u2018autoriza\u021bie condi\u021bionat\u0103 de introducere pe pia\u021b\u0103\u2019 \u00een Uniunea European\u0103 pentru terapia sa Ojemda, utilizat\u0103 pentru tratamentul unei forme rare de tumoare cerebral\u0103 la copii, informeaz\u0103 AFP. \u2018Comisia European\u0103 a acordat o autoriza\u021bie condi\u021bionat\u0103 de introducere pe pia\u021b\u0103 pentru Ojemda (tovorafenib)\u2019, tratament destinat pacien\u021bilor cu v\u00e2rsta de peste 6 luni, care sufer\u0103 de un gliom pediatric cu evolu\u021bie lent\u0103, \u00een recidiv\u0103 sau \u00een progresie \u00een pofida altor tratamente, conform unui comunicat. Autoriza\u021bia actual\u0103 este acordat\u0103 pe baza unor date clinice promi\u021b\u0103toare, dar \u00eenc\u0103 incomplete.<\/p>\n<p>Laboratorul va trebui s\u0103 demonstreze \u00een mod definitiv beneficiul clinic al tovorafenib prin studii suplimentare. Acest laborator a achizi\u021bionat drepturile asupra tovorafenib \u00een afara Statelor Unite \u00een 2024, de la Day One Biopharmaceuticals. \u2018Prioritatea noastr\u0103 este acum s\u0103 garant\u0103m accesul c\u00e2t mai rapid posibil la acest tratament pentru copiii eligibili din toat\u0103 Europa\u2019, a declarat Ipsen, subliniind c\u0103 \u2018mai pu\u021bin de 10% din noile autoriza\u021bii de medicamente din ultimii cinci ani au vizat boli pediatrice\u2019.<\/p>\n<p>\u00cen fiecare an, \u00een Uniunea European\u0103, peste 800 de copii sunt diagnostica\u021bi cu un gliom pediatric de grad sc\u0103zut, cu o muta\u021bie genetic\u0103 (cea a genei BRAF). Aceast\u0103 tumoare cerebral\u0103 duce frecvent la deficien\u021be fizice \u0219i neurologice severe, \u00een special la pierderea vederii, tulbur\u0103ri de vorbire \u0219i disfunc\u021bii motorii, care pot afecta \u00een mod semnificativ parcursul \u0219colar, autonomia \u0219i calitatea vie\u021bii pe termen lung, a explicat laboratorul. P\u00e2n\u0103 \u00een prezent, mul\u021bi copii afecta\u021bi erau nevoi\u021bi s\u0103 suporte opera\u021bii complexe \u0219i tratamente de chimioterapie \u0219i radioterapie, noteaz\u0103 AFP.\u00a0<\/p>\n<\/div>\n<\/div>\n<p>[analyse_source url=&#8221;https:\/\/www.monitoruldevrancea.ro\/2026\/04\/23\/cancer-pediatric-unda-verde-conditionata-in-europa-pentru-un-tratament-al-companiei-ipsen\/&#8221;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[analyse_image type=&#8221;featured&#8221; src=&#8221;https:\/\/www.monitoruldevrancea.ro\/wp-content\/uploads\/2026\/04\/Cancer-pediatric.jpg&#8221;] Grupul farmaceutic francez Ipsen a anun\u021bat miercuri c\u0103 a ob\u021binut o \u2018autoriza\u021bie condi\u021bionat\u0103 de introducere pe pia\u021b\u0103\u2019 \u00een Uniunea European\u0103 pentru terapia sa Ojemda, utilizat\u0103 pentru tratamentul unei forme rare de tumoare cerebral\u0103 la copii, informeaz\u0103 AFP. \u2018Comisia European\u0103 a acordat o autoriza\u021bie condi\u021bionat\u0103 de introducere pe pia\u021b\u0103 pentru Ojemda (tovorafenib)\u2019, tratament [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[89],"tags":[226,209],"class_list":["post-1901084","post","type-post","status-publish","format-standard","hentry","category-romania","tag-crawlmanager","tag-monitoruldevrancea-ro"],"_links":{"self":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/posts\/1901084","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1901084"}],"version-history":[{"count":0,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/posts\/1901084\/revisions"}],"wp:attachment":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1901084"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1901084"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1901084"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}